STAR Share Price Performance
₹996.50
355.75 (55.52%)
10.9% undervalued intrinsic discount
₹1,119.00
Fair Value
Price ₹996.50
AnalystLowTarget ₹1,119.00
AnalystConsensusTarget ₹1,078.50
AnalystHighTarget ₹1,409.00
Fair Value₹1,119.00
Share Pricen/a
Strides Pharma Science Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
STAR Community Narratives
AN
Fair Value ₹1.12k 10.9% undervalued intrinsic discount
US Market Dependency Will Strain Margins Yet Yield Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹1.08k 7.6% undervalued intrinsic discount
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value ₹1.41k 29.3% undervalued intrinsic discount
Aging Populations And Emerging Markets Will Energize Generic Demand
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US Market Dependency Will Strain Margins Yet Yield Opportunity
Key Takeaways Heavy reliance on the US market and supply chain risks could create earnings volatility and slow global expansion efforts. Intensifying competition, regulatory pressures, and shifting pharmaceutical trends may limit further margin gains and long-term growth potential.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹1.12k
10.9% undervalued intrinsic discount
Fair Value
Revenue
17.4% p.a.
Profit Margin
13.99%
Future PE
13.69x
Price in 2029
₹1.59k
Aging Populations And Emerging Markets Will Energize Generic Demand
Key Takeaways Strides is achieving stronger margins and growth than expected, driven by portfolio rationalization, operational enhancements, and effective entry into less competitive, higher-margin products. Expansion into differentiated products and emerging markets is reducing risk and supporting sustainable, stable revenue and earnings growth.Read more
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹1.41k
29.3% undervalued intrinsic discount
Fair Value
Revenue
19.07% p.a.
Profit Margin
14.35%
Future PE
16.11x
Price in 2029
₹2k
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
Key Takeaways Expansion in high-value generics, R&D investments, and digital transformation are driving diversified growth and long-term profitability across regulated and emerging markets. Streamlined product portfolio, cost optimization, and supply chain efficiencies are boosting margins and supporting sustainable earnings improvement.Read more
46
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
₹1.08k
7.6% undervalued intrinsic discount
Fair Value
Revenue
12.93% p.a.
Profit Margin
13.75%
Future PE
15.5x
Price in 2028
₹1.53k
Trending Discussion
Recently Updated Narratives
AN
STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis
Fair Value: ₹1.12k 10.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
STAR: Higher Revenue Assumptions Will Support Stronger Profit Margins Ahead
Fair Value: ₹1.41k 29.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
Fair Value: ₹1.08k 7.6% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Strides Pharma Science Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 55.49
- 56.20%
- 10.82%
- 65.8%
About STAR
- Founded
- 1990
- Employees
- 3301
- CEO
- WebsiteView website
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
